These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20614946)

  • 1. Current and future management options for myelodysplastic syndromes.
    Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H
    Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies for myelodysplastic syndromes.
    Steensma DP
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):423-41. PubMed ID: 20359635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk-based management of myelodysplastic syndrome.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
    Robak T; Szmigielska-Kapłon A; Pluta A; Grzybowska-Izydorczyk O; Wolska A; Czemerska M; Wierzbowska A
    Curr Med Chem; 2011; 18(5):638-66. PubMed ID: 21182488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine in the treatment of myelodysplastic syndromes.
    Bryan J; Kantarjian H; Prescott H; Jabbour E
    Expert Opin Investig Drugs; 2014 Feb; 23(2):255-63. PubMed ID: 24410313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine for myelodysplastic syndromes.
    Tiu RV; Traina F; Sekeres MA
    Expert Opin Investig Drugs; 2011 Jul; 20(7):1005-14. PubMed ID: 21591997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel biospecific agents for the treatment of myelodysplastic syndromes.
    Gotlib J; Greenberg PL
    J Natl Compr Canc Netw; 2003 Oct; 1(4):473-80. PubMed ID: 19774739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
    Garcia-Manero G; Fenaux P
    J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Supportive therapy for myelodysplastic syndrome (MDS). Indispensable pillar in the multimodal treatment concept].
    Göbel A; Lubrich B
    Pharm Unserer Zeit; 2010 May; 39(3):228-33. PubMed ID: 20425777
    [No Abstract]   [Full Text] [Related]  

  • 14. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel medical treatment modalities in hematology].
    Hasselbalch HC; Birgens H; Dufva IH; Dalseg AM; Brown Pde N; Jensen MK; Vangsted A
    Ugeskr Laeger; 2008 Jun; 170(24):2115-9. PubMed ID: 18565291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors in myelodysplastic syndromes.
    Steensma DP
    Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of myelodysplastic syndromes in the geriatric patient.
    Ritchie EK; Lachs MS
    Curr Hematol Malig Rep; 2009 Jan; 4(1):3-9. PubMed ID: 20425432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of MDS: something old, something new, something borrowed..
    Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of myelodysplastic syndromes: 2008 update.
    Scott BL; Estey E
    Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.